Trade Mark Journal No.2025/046 14 November 2025
WO0000001876367 (5,42,44)
Office of origin: United States of America
Date of International Registration:14 April 2025
Date of designation in the UK:
14 April 2025
International priority date claimed: 17 October 2024
(United States of America)
(98806908)
International priority date claimed: 17 October 2024
(United States of America)
(98806913)
International priority date claimed: 17 October 2024
(United States of America)
(98806917)
- Class 5
- Pharmaceutical preparations for the treatment of genetic, central nervous system, and lysosomal storage diseases and disorders; gene therapy products for the treatment of genetic, central nervous system, and lysosomal storage diseases and disorders, namely, virus vector-based gene therapy preparations for intravenous delivery.
- Class 42
- Pharmaceutical, scientific, and medical research and development in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; scientific research in the nature of conducting clinical trials for others in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; scientific and medical research, namely, compiling and sharing of patient data for research purposes in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; providing medical and scientific research information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; providing medical research and scientific research information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; pharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of gene therapy, genetic, central nervous system, and lysosomal storage diseases and disorders; biomedical research in the field of gene therapy design and delivery; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery.
- Class 44
- Providing medical services in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; medical consulting services in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; healthcare services, namely, medical and healthcare information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders, featuring inputting and collection of data and information on genetic, central nervous system, and lysosomal storage diseases and disorders for screening, diagnosis and treatment purposes via an online database; medical information services in the nature of providing information in the field of genetic, central nervous system, and lysosomal storage disease and disorder information based on collected patient data and information all for treatment and diagnostic purposes via a database; providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of genetic, central nervous system, and lysosomal storage diseases and disorders.
Ultragenyx Pharmaceutical Inc.
Representative: Cooley (UK) LLP, 22 Bishopsgate London EC2N 4BQ UNITED KINGDOM